Bernard J Zovighian to sell Edwards Lifesciences (EW) shares under Rule 144

Rhea-AI Filing Summary

Edwards Lifesciences Corp insider Bernard J Zovighian filed a Rule 144 notice to sell 22,430 shares of common stock, with an aggregate market value of $1,719,742.00. The proposed sale is through Charles Schwab & Co., Inc. on the NYSE around 02/12/2026.

The notice states that 580,300,000 shares of common stock were outstanding; this is a baseline figure, not the amount being sold. It also lists prior sales over the past three months of 21,487 and 3,863 Edwards Lifesciences shares, with gross proceeds of $1,831,006.00 and $322,367.00, respectively.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	22430	1719742.00	580300000	02/12/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/12/2026	Employee Stock Option Exercise	EDWARDS LIFESCIENCES CORPORATION			22430	02/12/2026	Broker Payment for Cashless Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Bernard J Zovighian ONE EDWARDS WAY IRVINE CA 92614	Edwards Lifesciences Corp	12/08/2025	21487	1831006.00
Bernard J Zovighian ONE EDWARDS WAY IRVINE CA 92614	Edwards Lifesciences Corp	12/10/2025	3863	322367.00

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Edwards Lifesciences (EW) Form 144 filing disclose?

The filing discloses that Bernard J Zovighian intends to sell 22,430 Edwards Lifesciences common shares under Rule 144. The planned sale has an aggregate market value of $1,719,742.00 and will be executed through Charles Schwab & Co., Inc. on the NYSE.

How many Edwards Lifesciences (EW) shares are planned to be sold and what is their value?

Bernard J Zovighian plans to sell 22,430 Edwards Lifesciences common shares with an aggregate market value of $1,719,742.00. The transaction is to be executed via Charles Schwab & Co., Inc., with trading expected around 02/12/2026 on the NYSE.

What prior Edwards Lifesciences (EW) share sales by Bernard J Zovighian are listed?

The notice lists two prior sales in the past three months: 21,487 Edwards Lifesciences shares sold on 12/08/2025 for gross proceeds of $1,831,006.00, and 3,863 shares sold on 12/10/2025 for $322,367.00 in gross proceeds.

How were the Edwards Lifesciences (EW) shares being sold acquired?

The 22,430 shares to be sold were acquired on 02/12/2026 through an Employee Stock Option Exercise from Edwards Lifesciences Corporation. Payment for the shares was made via a broker payment for a cashless exercise, according to the filing details.

What does the Form 144 say about Edwards Lifesciences (EW) shares outstanding?

The notice states that 580,300,000 Edwards Lifesciences common shares were outstanding. This figure provides context for the company’s total share base and is separate from the 22,430 shares covered by the planned Rule 144 sale in the filing.

On which exchange will the Edwards Lifesciences (EW) shares be sold?

The filing indicates the NYSE as the securities exchange where the 22,430 Edwards Lifesciences common shares are expected to be sold. Charles Schwab & Co., Inc., based in Westlake, Texas, is listed as the broker handling the planned transaction.